Acucela Inc.

acucela.com

Acucela Inc. (www.acucela.com or www.acucela.jp) is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

CADENCE COMPLETES ACQUISITION OF OPENEYE SCIENTIFIC

Cadence | September 05, 2022

news image

Cadence Design Systems, Inc. announced today that it has completed the acquisition of OpenEye Scientific Software, Inc. The addition of OpenEye’s technologies and experienced team accelerates the Cadence® Intelligent System Design™ strategy by extending Cadence’s computational software core competency to molecular modeling and simulation that is targeted to life sciences. OpenEye, an industry leader in computational molecular design, has pioneered physics-bas...

Read More

SIEMENS AND EXYTE JOIN FORCES ON MODULAR BIOTECH FACILITIES

Siemens | June 11, 2020

news image

Siemens, a process automation specialist, and Exyte, a biopharmaceutical manufacturing facility provider, have joined forces to offer end-to-end solutions for the biopharmaceutical industry.Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they...

Read More

FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO SUPPORT COVID-19 VACCINE CANDIDATE MANUFACTURING

FUJIFILM Diosynth Biotechnologies | July 28, 2020

news image

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...

Read More

Medical

PRECISION NANOSYSTEMS IS NOW A PART OF DANAHER'S LIFE SCIENCES PLATFORM

Cytiva, Pall Corporation | June 02, 2021

news image

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danahe...

Read More
news image

Cell and Gene Therapy

CADENCE COMPLETES ACQUISITION OF OPENEYE SCIENTIFIC

Cadence | September 05, 2022

Cadence Design Systems, Inc. announced today that it has completed the acquisition of OpenEye Scientific Software, Inc. The addition of OpenEye’s technologies and experienced team accelerates the Cadence® Intelligent System Design™ strategy by extending Cadence’s computational software core competency to molecular modeling and simulation that is targeted to life sciences. OpenEye, an industry leader in computational molecular design, has pioneered physics-bas...

Read More
news image

SIEMENS AND EXYTE JOIN FORCES ON MODULAR BIOTECH FACILITIES

Siemens | June 11, 2020

Siemens, a process automation specialist, and Exyte, a biopharmaceutical manufacturing facility provider, have joined forces to offer end-to-end solutions for the biopharmaceutical industry.Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they...

Read More
news image

FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO SUPPORT COVID-19 VACCINE CANDIDATE MANUFACTURING

FUJIFILM Diosynth Biotechnologies | July 28, 2020

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...

Read More
news image

Medical

PRECISION NANOSYSTEMS IS NOW A PART OF DANAHER'S LIFE SCIENCES PLATFORM

Cytiva, Pall Corporation | June 02, 2021

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danahe...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy

VIA Thaw™ automated dry thawer

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us